NCT02386644

Brief Summary

This study's aim is to evaluate diagnostic accuracy of transperineal ultrasound assessment compared with speculum examination, nitrazine and placental micro globulin-1 tests.

Trial Health

87
On Track

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Enrollment
105

participants targeted

Target at P50-P75 for not_applicable

Timeline
Completed

Started Feb 2015

Shorter than P25 for not_applicable

Geographic Reach
1 country

1 active site

Status
completed

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

Study Start

First participant enrolled

February 1, 2015

Completed
20 days until next milestone

First Submitted

Initial submission to the registry

February 21, 2015

Completed
19 days until next milestone

First Posted

Study publicly available on registry

March 12, 2015

Completed
20 days until next milestone

Primary Completion

Last participant's last visit for primary outcome

April 1, 2015

Completed
Same day until next milestone

Study Completion

Last participant's last visit for all outcomes

April 1, 2015

Completed
Last Updated

April 14, 2015

Status Verified

April 1, 2015

Enrollment Period

2 months

First QC Date

February 21, 2015

Last Update Submit

April 11, 2015

Conditions

Outcome Measures

Primary Outcomes (1)

  • True positive and negative percent agreement between transperineal assessment and PAMG-1 immunoassay as reference test.

    True positive rate and true negative rate of transperineal assessment will be calculated in percentages compared to PAMG-1 immunoassay as reference test.

    Up to 3 months

Study Arms (1)

Suspected Membrane Rupture Arm

EXPERIMENTAL

Women with suspected membrane rupture will be subject to following interventions; Ultrasound amniotic fluid index measurement, ultrasound transperineal assessment, nitrazine test, speculum examination, PAMG-1 Immunoassay

Other: PAMG-1 ImmunoassayDevice: Ultrasound transperineal assessmentDevice: Ultrasound amniotic fluid index measurementOther: Speculum examinationOther: Nitrazine test

Interventions

Immunoassay for presence of placental alfa microglobulin-1(PAMG) in vaginal fluids.

Also known as: AmniSure test (AmniSure International LLC, Boston, USA)
Suspected Membrane Rupture Arm

Transperineal ultrasound assessment of vaginal canal for pooling of amniotic fluid.

Suspected Membrane Rupture Arm

Calculation of amniotic fluid index in millimetres via ultrasonography by measuring four deepest pockets in four quadrants.

Suspected Membrane Rupture Arm

Sterile speculum examination to evaluate vaginal pooling of amniotic fluid pooling.

Suspected Membrane Rupture Arm

To assess acid , alkaline status of pooled fluid in vagina.

Suspected Membrane Rupture Arm

Eligibility Criteria

Sexfemale
Healthy VolunteersYes
Age GroupsChild (0-17), Adult (18-64), Older Adult (65+)

You may qualify if:

  • Women with early and late preterm pregnancies, (i.e., women above 24th and below 37th week of gestation)
  • Pregnant women with a complaint of fluid leakage

You may not qualify if:

  • Women with term pregnancies (i.e., women above 37th week of gestation)
  • Women with unviable pregnancies (i.e., women below 24th week of gestation)
  • Women in active labor (i.e., cervical dilatation above 4cm during admission)
  • Women with vaginal bleeding

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

Ankara University Faculty of Medicine, Department of Obstetrics and Gynecology

Ankara, 06100, Turkey (Türkiye)

Location

MeSH Terms

Conditions

Preterm Premature Rupture of the Membranes

Study Officials

  • Acar F Koc, Professor

    Department of Obstetrics and Gynecology, Ankara University Faculty of Medicine

    STUDY DIRECTOR

Study Design

Study Type
interventional
Phase
not applicable
Allocation
NA
Masking
NONE
Purpose
DIAGNOSTIC
Intervention Model
SINGLE GROUP
Sponsor Type
OTHER
Responsible Party
PRINCIPAL INVESTIGATOR
PI Title
Medical Doctor

Study Record Dates

First Submitted

February 21, 2015

First Posted

March 12, 2015

Study Start

February 1, 2015

Primary Completion

April 1, 2015

Study Completion

April 1, 2015

Last Updated

April 14, 2015

Record last verified: 2015-04

Locations